FDA Holds Historic Public Hearing on Psychedelic Therapies
On September 14, 2026, the Food and Drug Administration (FDA) convened a highly anticipated public hearing at its White Oak campus in Silver Spring, Maryland, focused squarely on provider credentialing, patient safety, data standardization, and equitable access.
Titled “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing,” the hearing marked the beginning of a multi-day stretch of gatherings featuring federal health officials, clinical stakeholders, and drug developers coming together to map out an evolving, and sometimes contradictory, architecture for psychedelic medicine. The proceedings underscored both a surging administrative momentum across federal agencies and the complex operational bottlenecks threatening to delay patient access.
Many stakeholders at the White Oak hearing warned that over-regulation could stifle the very access the agency hopes to facilitate. Laurel Kilgour of the Psychedelic Bar Association explicitly urged the agency to study ongoing, state-regulated access models to understand the financial friction created by stringent oversight. Addressing Risk Evaluation and Mitigation Strategy (REMS), Kilgour argued that “REMS should not limit access to patient care.” She noted that “the track records of regulatory frameworks that have been in place for multiple years in Oregon and Colorado are instructive about barriers to entry and how these programs are playing out in practice.”
Kilgour emphasized that preventing possible monopolies on therapeutic treatments is fundamentally a patient safety issue, telling the panel that “meaningful choice among providers is itself a kind of safeguard, a consumer protection.” She urged the FDA to ensure that credentialing requirements remain financially viable for small, independent providers.
Adding an international lens to the commercialization debate, Greg Hutchinson, chairman and investor at Australian Stock Exchange-listed Emyria Limited, described his country’s clinical landscape three years after their equivalent regulatory agency authorized psychiatrists to prescribe MDMA and psilocybin outside of investigative trials. Hutchinson reported that Emyria has successfully conducted over 500 dosing sessions under strict clinical governance, with treatments now funded by Australia’s largest health insurer and its Veterans Affairs department.
Hutchinson stressed that commercialization quickly outpaces the sterile environment of clinical studies, explaining that “real-world patients are more complex than trial patients, and we accept individuals that trials would typically exclude,” including those with elevated blood pressure and personality disorders. The success of these programs relies heavily on ongoing data collection, Hutchinson noted, observing that “trials set the starting point, but frontline providers armed with data advance the field.”
Education, Representation, and Data Deficits
Those present at the meeting observed that translating psychedelic-assisted therapies to the broader public requires overcoming what they see as a large educational deficit across the general healthcare workforce. Sandy Samberg, a nurse practitioner and founder of the Psychedelic Education Partnership, highlighted how mainstream providers remain entirely unprepared for novel psychiatric therapies. She recounted the story of a relative who had failed ten depression medications, only to have his internist, psychiatrist, therapist, and cardiologist all express confusion or reluctance regarding an esketamine nasal spray.
“Four highly trained, caring healthcare professionals, and not one of them felt equipped to help him navigate a treatment that had received FDA approval six years earlier,” Samberg stated. She argued that specialized facilitator training is insufficient on its own, asserting that “responsible integration also requires equipping a wide range of providers with the knowledge and confidence to discuss the evidence, risks, and contraindications, and make appropriate referrals.”
Beyond clinical education, data representation and structural equity also emerged as critical factors for the evolving regulatory framework. Jean C. Velez Rodriguez, a U.S. Marine Corps veteran and executive director of the Puerto Rico Institute for Puerto Rico Institute for Psychedelic Science, Medicine, and Awareness (PRISMA), revealed that 53% of participants in a recent local study reported lifetime psilocybin use. Yet, because the National Survey on Drug Use and Health utilizes a 50-state design, nearly 3.2 million American citizens in Puerto Rico are excluded from the foundational datasets guiding federal policy. “Territory inclusion should be a foundational design requirement for any federally endorsed data repository or coordinated registry network,” Rodriguez testified, warning the FDA that without intentional software engineering at the outset, “in our hands, we have a system that wasn’t built to see us.”
Velas Rodriguez’s testimony comes at a prescient time for Puerto Rican psychedelic advocates. In August, Puerto Rico Governor Jenniffer González-Colón signed an executive order establishing a psychedelic therapy and research pilot program under the direction of the Department of Health that will expedite research into ibogaine, MDMA, and other psychedelic compounds.
Lakesha Jenkins-Samuels of the Kiona Foundation echoed these structural concerns, pointing to persistent ambiguities in the therapeutic cannabis rollout as a cautionary tale. She demanded transparent botanical drug characterization, independent harm-reporting channels, and the direct inclusion of indigenous lineage keepers in the regulatory drafting process. “Keep space for the people who traditionally hold this medicine. They belong in the room where the rules are written,” Samuels urged the panel, firmly concluding that “community governance is safety infrastructure. Those are the simple facts.”
Legislating the Commercial Rollout
The commercial stakes surrounding traditional plant therapies are concurrently accelerating on Capitol Hill with the introduction of the Advancing Botanical Drug Development Act of 2026 (H.R. 10150). The legislation seeks to spur private investment in complex plant-based medicines, including cannabis and psychedelics, by granting FDA-approved botanical drugs a 12-year market exclusivity period during which generic competitors cannot be approved. Proponents argue this extended protection window is necessary to offset the unique scientific, standardization, and manufacturing costs associated with multi-pathway botanical formulations, which currently place them at a financial disadvantage compared to conventional single-molecule synthetic drugs.
However, this legislative push to secure extended corporate monopolies over natural compounds directly complicates advocates’ calls for open community governance, raising fundamental questions about whether the FDA’s existing regulatory frameworks can successfully reconcile traditional indigenous plant stewardship with modern, proprietary pharmaceutical mandates.
The measured, highly structured pace of the FDA’s White Oak hearing contrasted sharply with the energy of the Advanced Research Projects Agency for Health (ARPA-H) Ascent-IBO proposers meeting that was held the very next day on September 15. Dialing in remotely, Matt Zorn, Deputy General Counsel at HHS and the administration’s so-called “Psychedelics Czar,” challenged translational researchers to break out of their silos and form diverse, high-speed consortia. Pointing to the necessity of combining academic cardiologists, traditional knowledge keepers, and clinical trial runners, Zorn emphasized that “a lot of you here today are worth more on a team than you are individually.”
Zorn laid bare the administration’s expectations for rapid evidence generation for indications like opioid use disorder and severe PTSD. “It’s our responsibility to move fast, it’s our responsibility to fail quickly,” he declared, warning proposers that federal backing will strongly favor teams engineered for immediate velocity. Delivering a blunt final mandate to the attendees, Zorn stated, “We’re not going to fund someone who’s not going to move quickly.”
The regulatory shifts leading up to the hearing were substantial. Just days prior, on September 9, four senior FDA officials published a redefined roadmap in the New England Journal of Medicine titled, “FDA’s New Framework for Psychedelic Drugs” – detailing the agency’s openness to short-term efficacy approvals paired with robust post-market Risk Evaluation and Mitigation Strategies (REMS). The commentary also signaled flexibility on novel trial designs to address methodological challenges like functional unblinding.
This regulatory posturing coincided with broader federal alignment, including President Trump’s Executive Order 11401, signed on April 18 and designed to accelerate severe mental illness treatments and leadership stabilization across the Department of Health and Human Services (HHS). This includes the appointment of former Usona Institute Chief Medical Officer Michael Davis as Director of the Center for Drug Evaluation and Research. Most recently, the FDA granted a second Breakthrough Therapy Designation to Definium Therapeutics for the drug developer’s promising oral LSD compound for Major Depressive Disorder (MDD).
With the FDA’s public comment period remaining open through October 5, the contrasting discussions across Silver Spring and Washington outline the central tension currently facing the sector.
As regulators attempt to construct airtight safety mechanisms and community safeguards, federal health officials and agencies are actively driving to compress development timelines, leaving stakeholders to navigate a high-stakes balancing act between clinical caution and rapid therapeutic delivery.